SCHEMBL5530177

SCHEMBL5530177

CCOC(=O)c1cccc(NC(=S)NC2CCC(Nc3nc(N(C)C)c4ccccc4n3)CC2)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 14/20 0.61
ADRA2A P08913 13/20 0.61
HTR1A P08908 1/20 0.53
ADRA1A P35348 1/20 0.53
HRH1 P35367 1/20 0.53
HTR2B P41595 1/20 0.53
NPY5R Q15761 1/20 0.53
MAPT P10636 5/20 0.48
TP53 P04637 2/20 0.48
MEN1 O00255 2/20 0.46
ALDH1A1 P00352 2/20 0.46
KMT2A Q03164 2/20 0.46
NPC1 O15118 1/20 0.46
ABCB1 P08183 1/20 0.46
HTT P42858 1/20 0.46
RAB9A P51151 1/20 0.46
ABCG2 Q9UNQ0 1/20 0.46
MAPK1 P28482 2/20 0.45
LMNA P02545 1/20 0.45
TSHR P16473 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4040823 1.00 MCHR1 (0.61) MCHR1ADRA2AHTR1AADRA1AHRH1
SCHEMBL4036978 0.92 MCHR1 (0.62) MCHR1ADRA2AHTR1AADRA1AHRH1
SCHEMBL4036980 0.92 MCHR1 (0.62) MCHR1ADRA2AHTR1AADRA1AHRH1
SCHEMBL4028378 0.92 MCHR1 (0.62) MCHR1ADRA2AHTR1AADRA1AHRH1
SCHEMBL4028383 0.92 MCHR1 (0.62) MCHR1ADRA2AHTR1AADRA1AHRH1
SCHEMBL5524230 0.86 MCHR1 (0.56) MCHR1ADRA2AHTR1AADRA1AHRH1
SCHEMBL5524242 0.86 MCHR1 (0.56) MCHR1ADRA2AHTR1AADRA1AHRH1
SCHEMBL6869115 0.86 MAPT (0.48) MCHR1ADRA2AMAPTTP53MEN1
SCHEMBL6869121 0.86 MAPT (0.48) MCHR1ADRA2AMAPTTP53MEN1
SCHEMBL6868594 0.85 MAPT (0.47) MCHR1ADRA2AADRA1AHRH1HTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070010671-A1 Novel quinazoline derivatives and methods of treatment related to the use thereof ARENA PHARMACEUTICALS, INC. 2007-01-11 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010671-A1 Novel quinazoline derivatives and methods of treatment related to the use thereof MCHR1, GPR119, MCHR2 MCHR1 1/4885ADRA2A 103/4885HTR1A 61/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.